AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06596993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMU-based balance training
Description: Leveraging AI technology to identify motion deficiencies, the experimental group will undergo IMU-based balance training
Study NCT06596993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: general health education or exercise training
Description: general health education or exercise training
Study NCT06589011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support Ventilation
Description: The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min
Study NCT06589011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: spontaneously assisted breathing
Description: The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
Study NCT06600009 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: Patients had received secukinumab per their dosing regimens prior to this observational study.
Study NCT06600009 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Patients had received adalimumab per their dosing regimens prior to this observational study.
Study NCT06126731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40mg
Description: Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
Study NCT06126731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500mg
Description: Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder
Study NCT06126731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 400mg
Description: Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other
Study NCT06126731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 125mg
Description: Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass
Study NCT06126731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500g
Description: White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side
Study NCT05900687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of mHealth Question Prompt List app
Description: mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
Study NCT06589401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INP12
Description: Oral paclitaxel
Study NCT06588374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral internal sphincterotomy
Description: Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy
Study NCT06598748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Interface Mobilisation Technique
Description: In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).
Study NCT06598748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26).
Study NCT05983757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion
Description: The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems, and is also indicated for use as a conduit for retrieval devices.~The AXS Vecta Intermediate Catheter, as part of the AXS Vecta Aspiration System, is indicated in the revascularization of patients with acute ischemic stroke. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment.~The Trevo® Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA).
Study NCT05983757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical management
Description: All subjects should receive the best standard medical therapy based on current AHA guidelines. Subjects randomized to standard medical management (SMM) will receive standard medical therapy only based on the guidelines. All subjects are expected to be admitted to hospital as part of routine best guideline-based care and treated on a stroke unit or neurointensive care unit or equivalent.
Study NCT06591520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, Gemcitabine, Cisplatin
Description: AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
Study NCT06591520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab, Gemcitabine, Cisplatin
Description: Durvalumab will be administered at 1500mg intravenously (IV) every three weeks (Q3W) for 8 cycles and followed by monotherapy every 4 weeks. Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
Study NCT06588465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-venous Laser Irradiation of Blood
Description: The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
Study NCT06588465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low dose On-venous Laser Irradiation of Blood
Description: The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
Study NCT06592573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT_ONLINE
Description: 10-12 sessions of cognitive behavioural therapy conducted online
Study NCT06592573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT_IN PERSON
Description: 10-12 sessions of cognitive behavioural therapy conducted in-person.
Study NCT05525104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)
Description: This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration
Study NCT06596330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Validation of language model prompts in increasing short-term physical activity
Description: Aim 1: In preliminary data, the investigators have pre-trained an open-source language model, LLAMA, with expert-created coaching prompts based on the stages of change model for physical activity. Seven different prompts (for each day of an intervention week) will be generated, accounting for race/ethnicity, age, gender, and stage of change, to improve personalization. Using the existing MHC app, the investigators will perform a randomized crossover trial on mean daily steps across each intervention. The investigators will compare the interventions of a daily reminder to reach 10,000 steps (a neutral control) and AI-personalized interventions based on an individual's stage of change.
Study NCT06596330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Validation of language model prompts in increasing short-term physical activity
Description: Aim 1: In preliminary data, the investigators have pre-trained an open-source language model, LLAMA, with expert-created coaching prompts based on the stages of change model for physical activity. Seven different prompts (for each day of an intervention week) will be generated, accounting for race/ethnicity, age, gender, and stage of change, to improve personalization. Using the existing MHC app, the investigators will perform a randomized crossover trial on mean daily steps across each intervention. The investigators will compare the interventions of a daily reminder to reach 10,000 steps (a neutral control) and AI-personalized interventions based on an individual's stage of change.
Study NCT06596330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of long-term changes to physical activity and glycemic control
Description: Aim 2: Using social accountability and the trained language model generating personalized coaching interventions, the investigators will conduct a long-term follow-up randomized, unblinded trial. Over a 24-week intervention period, participants will receive either a generic daily reminder to reach 10,000 steps or an AI-generated coaching prompt, with the AI group also being able to chat with the language model to ask for advice on maintaining their physical activity. The outcomes of this long-term trial will be change in: 1) daily steps over the intervention period, 2) weight (via HealthKit link to MHC), and 3) HbA1c (as derived from EMR records linked to the HIPAA-compliant MHC app).
Study NCT06596330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of long-term changes to physical activity and glycemic control
Description: Aim 2: Using social accountability and the trained language model generating personalized coaching interventions, the investigators will conduct a long-term follow-up randomized, unblinded trial. Over a 24-week intervention period, participants will receive either a generic daily reminder to reach 10,000 steps or an AI-generated coaching prompt, with the AI group also being able to chat with the language model to ask for advice on maintaining their physical activity. The outcomes of this long-term trial will be change in: 1) daily steps over the intervention period, 2) weight (via HealthKit link to MHC), and 3) HbA1c (as derived from EMR records linked to the HIPAA-compliant MHC app).
Study NCT06587841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)
Description: The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
Study NCT06587841 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)
Description: The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
Study NCT06588075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction and fixation of zygomatico- Maxillary complex fracture using a full digital work flow
Description: All surgeries will be carried out under general anesthesia the fracture lines will be exposed then For the study group: following the exposure of all fracture lines , anatomically seated bone-supported predictive holes surgical guides will be inserted on the bone segments with intimate contact. Each segment hole will be drilled according to the predesigned predictive holes guide. The fractured segments will then be reduced and fixed using titanium miniplates customized for the patient and screws at least two screws for each fracture segment. then closure in layers will be performed using absorbable vicryl for deep layers and intraoral sutures and non-absorbable polyproline for skin closure.
Study NCT06588075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction and fixation of zygomatico- maxillary complex fracture using a conventional free hand protocol
Description: For the control group: all cases will be treated under general anesthesia and the fracture lines will be exposed then the conventional protocol of treatment depend mainly on visualization of the fracture line and tactile sensation of the operator intra-operative during reduction procedure and the fixation of fractured segments will be done using titanium miniplates and screws then closure in layers will be performed.
Study NCT06595836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Lubricated Synthetic polyisoprine condom
Description: Synthetic polyisoprene condom are made from softer materials for a more natural feel and increased sensitivity
Study NCT06595836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Lubricated Natural Rubber Latex Condom
Description: Natural rubber latex condoms are made from natural rubber
Study NCT06604507 — intervention group
Intervention type: DEVICE
Intervention: non-pharmacological app
Description: Amputees will be offered use of an app which offers a variety of non-pharmacological management techniques and exercises aimed at reducing the sensations and pain which are associated with amputation. These include: (1) offering information about the amputation, (2) augmented reality, this is a method for altering a person's perception about the real-world environment using computer simulation; (3) methods for reducing stress, also called 'Mindfulness-Based-Stress-Reduction' and (4) a method called 'Graded Motor Imagery' which aims to train the brain to address the changes which have occurred due to the amputation and which are related to pain and challenges with movement
Study NCT06595498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)
Description: The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).
Study NCT06595498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cobas® EGFR Mutation Test v2 (Roche)
Description: The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).
Study NCT06604377 — intervention group
Intervention type: OTHER
Intervention: Observe
Description: Ruijin
Study NCT06597604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative use of TenaTac in lung surgery
Description: Use of innovative medical device : TenaTac
Study NCT06597604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative use of usual sealant in lung surgery
Description: Use of the usual scealant as a control
Study NCT06595667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse pressure variation
Description: Fluid administration during posterior fossa surgery in the parkbench position is guided by the PPV value.
Study NCT06595667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous pressure
Description: Fluid administration during posterior fossa surgery in the parkbench position is guided by the CVP value.
Study NCT06586437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Assessments
Description: The participant will undergo a battery of clinical assessments to identify the upper extremity motor performance, sensory acuity, and ability to complete activities of daily living. Tests 1-5 will be completed separately for each hand. All participants will be video recorded while completing these assessments. The recordings will be used for grading tasks and data analysis: Box and Blocks, 9-hold peg board, Test of Arm Selective Control, Sensory Acuity Testing, KINARM End-Point Lab Sensory Test, Section GG of the inpatient Rehabilitaion Facility-Patient Assessment Instrument, NEURO-QOL Upper Extremity Function Scale, Edinburgh Handed Inventory
Study NCT06586437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain-Spinal Cord fMRI
Description: Resting state, brain-spinal cord activity, spinal cord microstructure, magnetic resonance spectroscopy
Study NCT06586437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hoffmann Reflex Assessments
Description: Hmax 20-50 stimulations of increasing intensity. Next, the participant will sit quietly as 10 stimulations will be delivered at the participant's Hmax with an interstimulus interval of 15 seconds. Subsequently, stimulations at the participant's Hmax will be applied as the participants produce a contraction of 10-20% of their maximum voluntary contraction (MVC). The target contraction level will be shown in real-time based on the FCR EMG activity. The participant maintains their EMG activity at the target level for 6.5 seconds as 10 stimulations are delivered at the participants Hmax.
Study NCT06586437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEG Imaging
Description: Resting state, somatosensory, isometric force matching, entrainment
Study NCT06586437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcutaneous Current Stimulation
Description: Cortical stimulation, spinal cord stimulation - sham and stim
Study NCT06599385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion if platelet count ≤ 10 G/L
Description: Platelet transfusion as soon as platelet count falls ≤ 10 G/L
Study NCT06599385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet transfusion when platelet count ≤ 20 G/L
Description: Platelet transfusion will be initiated immediately after randomisation
Study NCT06587971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard periodontal treatment protocol
Description: Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery.